FILING ANALYSIS · TUESDAY, OCTOBER 13
JOHNSON & JOHNSON JNJ — 8-K: Results of Operations and Financial Condition
positive
Johnson & Johnson reported a 5.9% increase in third-quarter sales and raised its 2026 guidance, with estimated reported sales of $101.2 billion and adjusted EPS of $11.10, driven by strong operational performance and innovation in its MedTech and pharmaceutical segments.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →